Combivent respimat and Atelectasis - a phase IV clinical study of FDA data

Summary:

No or few reports are found.

The phase IV clinical study is created by eHealthMe based on reports from the FDA, and is updated regularly.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 700+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Oct, 03, 2023

No or few reports are found.

What is Combivent Respimat?

Combivent respimat has active ingredients of albuterol sulfate; ipratropium bromide. It is used in chronic obstructive pulmonary disease. Currently, eHealthMe is studying from 2,439 Combivent respimat users.

What is Atelectasis?

Atelectasis (partial or complete collapse of the lung) is found to be associated with 2,461 drugs and 1,588 conditions by eHealthMe. Currently, we are studying 16,626 people who have Atelectasis.

Do you take Combivent respimat and have Atelectasis?

Check whether Atelectasis is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

Combivent respimat side effects by duration, gender and age:

Combivent respimat side effects (2,439 reports)

Atelectasis treatments and more:

Atelectasis (16,626 reports)

All the drugs that are associated with Atelectasis:

Atelectasis

All the conditions that are associated with Atelectasis:

Atelectasis

How the study uses the data?

The study uses data from the FDA. It is based on albuterol sulfate; ipratropium bromide (the active ingredients of Combivent respimat) and Combivent respimat (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 700+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.